Stay updated on Replagal Dosing in Fabry Disease: Cardiac Function Clinical Trial
Sign up to get notified when there's something new on the Replagal Dosing in Fabry Disease: Cardiac Function Clinical Trial page.

Latest updates to the Replagal Dosing in Fabry Disease: Cardiac Function Clinical Trial page
- Check4 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; removed the Back to Top element. No other substantive content changes.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility and location information related to Fabry disease and agalsidase alfa, while previous location terms and drug information have been removed.SummaryDifference2%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Replagal Dosing in Fabry Disease: Cardiac Function Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Replagal Dosing in Fabry Disease: Cardiac Function Clinical Trial page.